• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Viatris Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    6/18/26 4:10:51 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTRS alert in real time by email
    false000179204400017920442026-06-172026-06-17

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM 8-K



    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported): June 17, 2026



    VIATRIS INC.
    (Exact name of registrant as specified in its charter)



    Delaware
    001-39695
    83-4364296
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification Number)

    1000 Mylan Blvd., Canonsburg, PA 15317
    (Address of principal executive offices)

    (724) 514-1800
    (Registrant’s telephone number, including area code)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.01 per share
    VTRS
    The NASDAQ Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 1.01.
    Entry into a Material Definitive Agreement.
    On June 17, 2026, Viatris Inc. (“Viatris” or the “Company”) completed a public offering of €650,000,000 aggregate principal amount of its 4.250% Senior Notes due 2033 (the “Notes”). The Notes are senior unsecured obligations of Viatris.  The Notes are guaranteed on a senior unsecured basis by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc. (the “Guarantors”).
    The Company intends to use the net proceeds from the offering (i) to fund the repayment of any amounts borrowed under its senior unsecured revolving credit facility in June 2026 in connection with the repayment at maturity of the entire $1.675 billion of outstanding principal amount of the 3.950% Senior Notes due 2026 issued by Utah Acquisition Sub Inc. (the “2026 Senior Notes”) and (ii) the remainder, if any, to replenish cash that will be utilized in connection with the repayment of the 2026 Senior Notes, with such cash to be used for general corporate purposes.
    The Notes were issued pursuant to an Indenture (the “Base Indenture”), dated June 17, 2026, among the Company, the Guarantors and The Bank of New York Mellon, as trustee (the “Trustee”), as supplemented by the First Supplemental Indenture (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”), dated June 17, 2026, among the Company, the Guarantors and the Trustee (which includes the form of Notes as an exhibit). The offering of the Notes was registered on a Registration Statement on Form S-3 (File No. 333-287087).  The Notes will accrue interest at a rate of 4.250% per annum, accruing from June 17, 2026, payable annually beginning June 17, 2027, and will mature on June 17, 2033, subject to earlier repurchase or redemption in accordance with the terms of the Indenture.
    At any time prior to April 17, 2033 (the date that is two months prior to the maturity date of the Notes) (the ‘‘Par Call Date’’), the Company may redeem the Notes, in whole or in part, upon not less than 10 nor more than 60 days’ prior written notice, at a price equal to the greater of (1) 100% of the principal amount of the Notes to be redeemed, and (2) the sum of the present values, as calculated by the Company, of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the redemption date on an annual basis (ACTUAL/ACTUAL (ICMA) as defined in the rulebook of the International Capital Market Association), at the applicable Comparable Government Bond Rate (as defined in the Indenture) plus 25 basis points, plus, in either case, accrued and unpaid interest thereon to the redemption date. On or after the Par Call Date, the Company may redeem the Notes, in whole or in part, at a price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest thereon to the redemption date.

    If certain change of control events occur, the Company must offer to purchase the Notes from holders at a purchase price equal to 101% of the principal amount, plus accrued and unpaid interest thereon, if any, to, but excluding, the repurchase date, unless the Company has exercised its right to redeem the Notes.


    The Indenture contains covenants that, among other things, restrict the Company’s ability and the ability of certain of the Company’s subsidiaries to (1) enter into certain sale and leaseback transactions; (2) create certain liens; (3) with respect to such subsidiaries only, guarantee certain of the Company’s outstanding obligations without also guaranteeing the Company’s obligations under the Notes; and (4) with respect to the Company only, consolidate, merge or sell all or substantially all of the Company’s consolidated assets. The Indenture provides for customary events of default (subject in certain cases to customary grace and cure periods), which include nonpayment, breach of covenants, payment defaults or acceleration of other indebtedness, failure to pay certain judgments and certain events of bankruptcy and insolvency. These covenants and events of default are subject to a number of important qualifications, limitations and exceptions that are described in the Indenture. Upon occurrence of an Event of Default (as defined in the Indenture) with respect to the Notes, the principal amount of the Notes may be declared, and/or become, due and payable immediately.

    The above description of the Indenture and the Notes is qualified in its entirety by reference to the Indenture and the form of the Notes filed as exhibits hereto, which exhibits are incorporated by reference herein.
    Item 2.03.
    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
    The information set forth in Item 1.01 is incorporated herein by reference.
    Item 9.01.
    Exhibits.

    Exhibit
    Number
    Description of Exhibit
    4.1
    Indenture, dated June 17, 2026, among the Company, the Guarantors and The Bank of New York Mellon, as trustee.
    4.2
    First Supplemental Indenture, dated June 17, 2026, among the Company, the Guarantors and The Bank of New York Mellon, as trustee.
    4.3
    Form of 4.250% Senior Note due 2033 (included in Exhibit 4.2).
    5.1
    Opinion of Cravath, Swaine & Moore LLP.
    5.2
    Opinion of NautaDutilh N.V.
    5.3
    Opinion of Parker Poe Adams & Bernstein LLP.
    23.1
    Consent of Cravath, Swaine & Moore LLP (included in Exhibit 5.1).
    23.2
    Consent of NautaDutilh N.V. (included in Exhibit 5.2).
    23.3
    Consent of Parker Poe Adams & Bernstein LLP (included in Exhibit 5.3).
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: June 18, 2026

      VIATRIS INC.
         
     
    By:
    /s/ Matthew Maletta
       
    Matthew Maletta
       
    Chief Legal Officer



    Get the next $VTRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTRS

    DatePrice TargetRatingAnalyst
    2/9/2026$18.00Neutral → Buy
    UBS
    1/16/2026$15.00Hold → Buy
    Argus
    12/9/2025$15.00Overweight
    Barclays
    10/15/2025$15.00Buy
    Truist
    6/6/2025$10.00Neutral
    Goldman
    7/19/2024$15.00Buy
    Jefferies
    10/23/2023$13.00 → $9.00Neutral → Underperform
    BofA Securities
    6/23/2023$11.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $VTRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viatris Recognized as One of the 2026 Best Workplaces™ in Canada

    ETOBICOKE, ON, June 16, 2026 /CNW/ -- Viatris Inc. (NASDAQ:VTRS) has been recognized as one of the 2026 Best Workplaces™ in Canada by Great Place to Work®. This recognition highlights Viatris' commitment to fostering a culture where colleagues feel valued, engaged, and empowered to do meaningful work while making a positive impact on patients and communities.Great Place to Work® is the global authority on workplace culture, employee experience and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. This recognition is the result of an independent evaluation, which uses a rigorous two-step process that includes an anonymous survey to

    6/16/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

    FDA PDUFA Goal Date Set for Dec. 27, 2026PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026. Acute pain affects more than 80 million individuals in the United States each year, where opioids remain a commonly used treatment option.1,2 "FDA's acceptance of

    5/18/26 8:00:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

    PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m. ET.Investors and the general public are invited to listen to the live webcast of the event at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients

    5/7/26 4:30:00 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    SEC Filings

    View All

    Viatris Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Viatris Inc (0001792044) (Filer)

    6/18/26 4:10:51 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Viatris Inc (0001792044) (Filer)

    6/15/26 4:32:33 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Viatris Inc.

    FWP - Viatris Inc (0001792044) (Subject)

    6/12/26 4:10:32 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $VTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 4 filed by Le Goff Corinne

    4 - Viatris Inc (0001792044) (Issuer)

    4/16/26 6:00:28 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Campbell Paul

    4 - Viatris Inc (0001792044) (Issuer)

    3/24/26 6:04:35 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Viatris Inc.

    4 - Viatris Inc (0001792044) (Issuer)

    3/10/26 7:03:54 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris upgraded by UBS with a new price target

    UBS upgraded Viatris from Neutral to Buy and set a new price target of $18.00

    2/9/26 6:59:24 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris upgraded by Argus with a new price target

    Argus upgraded Viatris from Hold to Buy and set a new price target of $15.00

    1/16/26 8:41:55 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Viatris with a new price target

    Barclays initiated coverage of Viatris with a rating of Overweight and set a new price target of $15.00

    12/9/25 8:55:06 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Smith Scott Andrew bought $219,740 worth of shares (22,000 units at $9.99), increasing direct ownership by 8% to 314,807 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    8/13/25 6:08:30 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Smith Scott Andrew bought $536,262 worth of shares (60,000 units at $8.94), increasing direct ownership by 26% to 292,807 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    5/14/25 6:00:11 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    10/25/24 4:30:03 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Leadership Updates

    Live Leadership Updates

    View All

    Viatris Appoints Matthew J. Maletta as Chief Legal Officer

    Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 2026, to ensure a smooth transition

    2/3/26 8:30:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

    PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies. Ramsburg is an accomplished leader with more than 25 years of experience building and leading highly effective cross-functional

    1/8/26 9:05:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

    PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions. The consolidation of these areas centralizes leadership of the company's digital, cultural and structural transformation initiatives and is designed to accelerate the company's ongoing strategic evolution.

    8/19/25 9:00:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Financials

    Live finance-specific insights

    View All

    $VTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Viatris Reports First-Quarter 2026 Financial Results

    Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to First Quarter 2025Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First Quarter 2025, Demonstrating Solid Operating Leverage Progresses Key Launches and Pipeline Milestones Across Multiple Products, Including the Launch of Effexor® for Generalized Anxiety Disorder in JapanContinues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026Reaffirms 2026 Financial Guidance [1]PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced its fi

    5/7/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Announces Quarterly Dividend

    PITTSBURGH, May 5, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 17, 2026, to shareholders of record as of the close of business on May 22, 2026.About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed

    5/5/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Announces Chief Financial Officer Transition

    Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFOPITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the Company for a new professional opportunity.Viatris has named Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief Financial Officer, effective May 8, 2026, while the Company conducts its search for a permanent successor. Mistras will remain with the Company until May 22, 2026, to facilitate a seamless transition."We thank Doretta for her significant contributions, which have helped prepare the Company

    5/4/26 4:30:00 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viatris Inc.

    SC 13G/A - Viatris Inc (0001792044) (Subject)

    11/12/24 1:41:20 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Viatris Inc. (Amendment)

    SC 13G/A - Viatris Inc (0001792044) (Subject)

    2/13/24 5:17:31 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Viatris Inc.

    SC 13G - Viatris Inc (0001792044) (Subject)

    2/9/24 1:10:51 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care